Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	165.81	26.68	55.52	36.63	26.37
Short-Term Investments	539.93	875.94	306.56	118.85	175.73
Cash & Short-Term Investments	705.74	902.61	362.08	155.49	202.1
Cash Growth	-21.81%	149.29%	132.87%	-23.07%	-18.63%
Other Current Assets	9.86	4.6	5.15	11.56	8.43
Total Current Assets	715.6	907.22	367.23	167.04	210.53
Net Property, Plant & Equipment	0.09	1	1.13	1.42	0.03
Other Long-Term Assets	0.05	0.1	0.14	0.07	0.11
Total Assets	715.73	908.32	368.49	168.53	210.66
Accounts Payable	53.25	9.81	7.51	8.53	1.44
Accrued Expenses	23.28	17.11	11.3	13.11	7.31
Current Portion of Leases	0.14	0.49	0.32	0.3	0.03
Total Current Liabilities	76.67	27.41	19.14	21.95	8.78
Long-Term Leases	-	0.63	0.94	1.26	-
Total Long-Term Liabilities	-	0.63	0.94	1.26	-
Total Liabilities	76.67	28.04	20.07	23.21	8.78
Common Stock	0	0	0	0	0
Treasury Stock	-	-	-6.8	-6.8	-
Additional Paid-in Capital	1,486	1,369	733.55	445.27	425.61
Accumulated Other Comprehensive Income	0.38	-0.79	-0.39	-1.1	-0.55
Retained Earnings	-847.55	-487.91	-377.94	-292.05	-223.18
Shareholders' Equity	639.06	880.28	348.42	145.32	201.88
Total Liabilities & Equity	715.73	908.32	368.49	168.53	210.66
Total Debt	0.14	1.12	1.26	1.56	0.03
Net Cash (Debt)	705.6	901.49	360.82	153.92	202.07
Net Cash Growth	-21.73%	149.85%	134.42%	-23.83%	-18.53%
Net Cash Per Share	6.26	8.27	3.82	2.00	2.62
Book Value	639.06	880.28	348.42	145.32	201.88
Book Value Per Share	5.67	8.07	3.69	1.89	2.62
Tangible Book Value	639.06	880.28	348.42	145.32	201.88
Tangible Book Value Per Share	5.67	8.07	3.69	1.89	2.62

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q